CTRI/2017/09/009650尚未招募2 期
Rituximab with reduced dosage LMB backbone chemotherapy schedule in childhood and adolescent mature B cell lymphoma/leukemia: Evaluation of efficacy & toxicity profile in developing country setting - R LMB childhood lymphoma
Cancer Institute adyar0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1.CD 20 positive Burkitt lymphoma & Diffuse large B cell lymphoma stage III & IV stage
- •2.CD 20 positive Burkitt lymphoma & Diffuse large B cell lymphoma stage I & II stage non-resectable
排除标准
- •1.Active hepatitis B infection or carriers of hepatitis B virus
- •2.Active hepatitis C infection or carriers of hepatitis C virus
- •3.HIV infected children
- •4.Patients with congenital immunodeficiency, chromosomal breakage syndrome, prior organ transplantation, previous malignancy of any type, or known positive HIV serology
- •5.Follicular lymphoma, MALT, nodular marginal zone lymphoma and primary mediastinal B cell lymphoma
- •6.Children with cardiac dysfunction- ejection fraction < 45%
- •7.Pregnancy
- •8.Allergic to rituximab
- •9.Not consenting for treatment
- •10.Children assessed by treating physician as not fit for intensive chemotherapy
研究者
相似试验
进行中（未招募）
1 期
Very low doses of Rituximab for autoimmune diseases, for which rituximab is not approved for - a Pilot TrialAutoimmune-haemolytic AnemiaAntiphospholipid SyndromeImmune-mediated ThrombocytopeniaMedDRA version: 20.0Level: LLTClassification code 10003825Term: Autoimmune hemolytic anemiaSystem Organ Class: 100000154058MedDRA version: 20.0Level: LLTClassification code 10023095Term: ITPSystem Organ Class: 100000157088MedDRA version: 20.0Level: PTClassification code 10002817Term: Antiphospholipid syndromeSystem Organ Class: 10005329 - Blood and lymphatic system disordersEUCTR2016-002478-11-ATMedical University of Vienna, Department of Internal medicine I48
进行中（未招募）
1 期
Maintenance treatment With rituximab in ITPImmune thrombocytopeniaEUCTR2015-005276-14-DKSykehuset Østfold HF130
尚未招募
不适用
Study on the efficacy of rituximab in patients with polymyalgia rheumaticapolymyalgia rheumaticaNL-OMON27507one. This is an investigator initiated trial50
进行中（未招募）
不适用
Rituximab plus Bendamustine as front line treatment in frail elderly (=70 years) patients with diffuse large B-cell non-Hodgkin’s lymphoma: a phase II multicenter study of the Fondazione Italiana Linfomi (FIL)EUCTR2011-001421-24-ITFONDAZIONE ITALIANA LINFOMI ONLUS
招募中
2 期
Rituximab combined with gemcitabine, dexamethasone, and cisplatin in elderly patients with relapsed or refractory diffuse large B-cell lymphomaDiffuse large B-cell lymphomaJPRN-UMIN000015492ational Hospital Organization Kyushu Medical Center42